Abstract
Introduction
Cell tracking by magnetic resonance imaging (MRI) is an emerging method to visualize and monitor labeled cells after transplantation non-invasively and without the use of ionizing radiation. Recently, 19 F-fluorine-MRI has been used to detect and track well-defined cell populations [1] [2] [3] [4] [5] [6] [7] . Because of the effective absence of 19 F background signal in the body, any 19 F signal detected after injection of a 19 F compound is unequivocally produced by this injected compound. As the MR signal is directly proportional to the amount of 19 F nuclei present in the tissue, it can be related to a reference of known 19 F concentration, rendering this technique quantitative [3, 4] . Moreover, these compounds are not limited by signal decay over time and therefore the time window for their detection can last several days. Finally, the 19 F signal can be merged with conventional 1 H-MRI images to identify its exact anatomic location and to add information on structure, function, and tissue characteristics. Direct IV injection of emulsions containing 19 F-based perfluorocarbons (PFC) has been performed in different rodent models for angiography [8] and to detect non-invasively inflammation in myocardial infarction [5, 9] , cerebral ischemia [5] , myocarditis [6] , pneumonia [10] , atherosclerosis [11] , arthritis [12] and tumors infiltrated by macrophages [13] . Distinctively, defined cell populations such as dendritic cells [1] , T cells [3, 4, 14, 15] , or mesenchymal stem cells [16] were tracked non-invasively in rodents by 19 F-MRI or 19 F-MR spectroscopy ( 19 F-MRS) after their in-vitro 19 F-labeling.
Recently, clinical 19 F-MRI cell detection using labeling by PFC has also been described in patients with colorectal adenocarcinoma in order to detect autologous immunotherapeutic dendritic cells [7] . This technique could therefore be applied to detect tumor cells as well as to monitor adopted cell transfer cancer therapies.
In recent years adoptive cell transfer therapies using ex-vivo activated T cells have undergone intensive testing [17, 18] , and various types of T cells have been used for adoptive immunotherapy. It is essential to know whether the administered T cells reach their target and this is currently assessed by biopsies, which are invasive and not practical for all patients [18] . Also, with a biopsy-based approach the total amount of T cells in a tumor, their distribution, and the kinetics of cell fluxes are difficult to assess. Non-invasive visualization of the trafficking of administered T cells could potentially allow one to predict responsiveness to these therapies. Therefore, a reliable non-invasive imaging method to monitor anti-tumor cell traffic is highly desirable. Moreover, as T cells with specific anti-tumor properties can migrate to and infiltrate tumor tissue by recognizing tumor antigens [19] , they could, in principle, be used as a probe to detect tumor cells at metastatic sites when labeled with PFCs.
In the present study the migratory behavior of 3 different cell populations was tracked by means of non-invasive 19 + and these cytotoxic lymphocytes express one unique T cell receptor (TCR) called OT-1. To distinguish how the T cells were activated and expanded in-vitro, we named "T act " the T cells that were stimulated with anti-CD3 and anti-CD28 antibodies, and "T OVA-act " the cells derived from single-cell suspensions of dissociated spleens stimulated with the specific OVA 257-264 peptide. The OVA 257-264 antigen was used as a tumor-specific antigen in the current study, and T OVA-act and T act were produced from OT-1 mice expressing only the TCR OT-1 specific for K b -OVA [257] [258] [259] [260] [261] [262] [263] [264] which is expressed at the surface of B16-OVA tumor grafted on recipient mice.
Splenic-derived OT-1 CD8 + T cells, stimulated either by OVA-peptide (= T OVA-act ) or by anti-CD3 and anti-CD28 antibodies (= T act ) will expand and differentiate into various states including central memory (T CM ), effector memory (T EM ) and terminally differentiated, shortlived effector T cells (T E ). Importantly, the newly activated T cells will also maintain a high state of proliferation for several days. While T E cells are typically found in peripheral tissue and provide a critical first line of defense to foreign antigen, T CM cells migrate to areas of secondary lymphoid organs, and compared to naive T N cells have a higher sensitivity to antigen stimulation. T EM tend to home to inflamed tissues, and have a more rapid effector function as compared to T CM [20] . Activated tumor-antigen specific T OVA-act and T act were labeled in-vitro (by the same PFC as used for SP) to test for non-invasive in-vivo tracking by 19 F-MRS and 19 F-MRI in mice bearing a B16-OVA tumor. Accordingly, the aim of the study was to develop a reproducible protocol for the in-vitro 19 F-labeling of the three cell groups, to determine the detection limits of 19 F-MRS and 19 F-MRI for the in-vivo detection of these cells, and to test this application in B16-OVA tumor bearing mice.
Materials and Methods

Tumor Cells
B16-OVA melanoma cells (Ludwig Branch for Cancer Research, Lausanne) were maintained in Dulbecco's modified Eagle's medium (GIBCO Invitrogen, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (GIBCO Invitrogen) and penicillin-streptomycin (GIBCO Invitrogen).
Abs and reagents
Fluorescent antibodies against mouse CD3, CD4, CD8, CD19, CD11b, CD44, anti-CD62L, PD-1, CD127, CD45.2, CD107a and IFNγ were purchased from eBioscience (San Diego, CA). Purified anti-mouse CD3 and anti-mouse CD28 were from Biolegend (San Diego, CA 
Animals
All animal procedures were approved by the animal ethics committee (SCAV: Service de la Consommation et des Affaires Vétérinaires, Epalinges, Switzerland). All MR examinations were performed under ketamine-medetomidine anesthesia, and all efforts were made to minimize suffering. Mice were maintained under specific pathogen-free conditions. Ovalbuminspecific TCR transgenic (OT-1) mice were used to produce SP (described below). OT-1 mice were on a RAG1 -/-background. CD45.1 C57BL/6 mice were used as recipients for adoptive transfer (described below). Ten days prior to adoptive transfer, tumors were implanted subcutaneously and dorsolaterally with inoculations of 10 6 B16-F10-OVA melanoma cells in 50 μl saline in CD45.1 C57BL/6 mice [21] . The in-vivo protocol is depicted in Fig 1. 
T cell isolation and activation
Spleens from CD45.2 + OT1 mice were removed aseptically and homogenized by passing through a cell strainer (40μm). Red blood cells were lysed by the addition of a buffered ammonium chloride solution. The nucleated remaining cells (SP) were resuspended in complete medium (RPMI-1640 medium with 10% FBS, 100 μg/ml each of streptomycin and penicillin, 10 mM HEPES and supplemented with 2-mercaptoethanol) and two different protocols were applied to produce either T act or T OVA-act . The SP population was used immediately after .1 C57BL/6 mice received 10 6 B16-F10 melanoma cells by subcutaneous injection in order to induce a malignant melanoma. On the same day SP were prepared from OT-1 mice and two different protocols were applied to generate T act or T OVA-act (as described in Materials and Methods, T cells isolation and activation section). At day 8 (D8), PFC was added in the cell culture medium for 18h in order to label SP, T act and T OVA-act with 19 F. Then, at day 9 (D9) the 19 F-labeled cells were injected IV: 2 control mice (with no tumors) received 50 x 10 6 SP, 3 mice received 20 to 50 x 10 6 T act and 5 mice received 20 to 40 x 10 6 T OVA-act . Finally, 9 mice were imaged at day 10 (D10; 1 T act injected mouse was not imaged) and all mice were immediately sacrificed for subsequent analysis of the organs (liver, lungs, spleen and tumor) by flow cytometry (all mice) and high resolution in-vitro NMR spectroscopy (2 SP injected mice, 3 T OVA-act injected mice and 1 T act injected mouse). The study protocol was performed in a total of 10 animals. In black: in-vivo part; in blue: cell preparation. isolation for in-vitro FITC-conjugated or un-conjugated 19 F-labeling and dead cells were eliminated with Ficoll (GE Healthcare) prior to injection into CD45.1 + C57BL/6 mice. T act were obtained by stimulation of the SP population with recombinant murine IL2 (20 ng/ml), antimouse CD3 (500 ng/ml) and anti-mouse CD28 (0.1 μg/ml) for 2 days. T OVA-act were obtained by stimulation of the SP with the OVA peptide (SIINFEKL; 2 μg/ml) for 2 days in the presence of recombinant murine IL2 (20 ng/ml). In both protocols, two days after stimulation, clusters were formed and harvested to form a single-cell suspension. Dead cells were eliminated with Ficoll and cells were seeded in complete medium containing recombinant human IL15 at 20 ng/ml. Medium was changed every 2 days for one week.
Cell Labeling
SP, T act , and T OVA-act were labeled in-vitro with Cell Sense (CS-1000), a 19 F-based MR imaging agent. Cell Sense is an aqueous colloidal suspension (= nanoemulsion) of a perfluoropolyether perfluorocarbon polymer (PFC), having total fluorine content of 145 mg/mL (Celsense Inc., Pittsburg, PA, USA). The average nanoemulsion droplet size is 180 nm. It is formulated with excipients that facilitate PFC uptake into all cell types, regardless of their ability to phagocytose. The PFC used in Cell Sense is stable at low pH [22] . SP, T act , and T OVA-act were also labeled invitro with FITC conjugated PFC. In all conditions, PFC was added to the cell culture medium at a concentration of 10 mg/mL and incubated with the SP, T act , or T OVA-act for 18 hours at 37°C, 5% CO 2 (SP n = 5; T act n = 14; T OVA-act n = 10). After this incubation period, the cells were washed three times with PBS and counted.
High resolution in-vitro 19 F-NMR spectroscopy of labeled cells
In order to measure the mean 19 F spectra, acquired with 256 scans and processed with a line broadening of 5 Hz, contain several peaks with a major one located at -93 ppm and the TFA peak at -75 ppm. These two peaks were used for quantitative calculations.
Functional assay of PFC-FITC labeled cells
One hundred thousand SP, T act , and T OVA-act were cocultured with 50x10 5 B16-OVA tumor cells in the presence of anti-CD170a antibody and Golgi Stop reagent (BD Biosciences, San Jose, CA). After 5 hours of incubation at 37°C, cells were washed and stained with fluorescent anti-CD3 and anti-CD8 antibodies at 4°C for 20 minutes. Following fixation and permeabilization, the cells were stained with anti-IFNγantibody and analyzed on a FACS LSRII (BD Biosciences) and BD FACS Diva software. 
Cytotoxicity assay of PFC-FITC labeled cells
Adoptive transfer of T cells
The study protocol is shown in Fig 1. PFC 
F-MRI
The day after adoptive transfer (24h to 36h post injection, Fig 1) mice were anesthetized with intraperitoneal injection of ketamine: medetomidine (75 mg/kg: 0.1 mg/kg). This anaesthetic combination was chosen to avoid any isoflurane 19 F-MR background signal resulting from its accumulation in the fat pads [23] . The body temperature was monitored with a rectal probe (SA Instruments, Stony Brook, NY) and kept constant at 37.0°C by using tubing with circulating warm water. The animals were placed under a custom-designed 18-mm diameter quadrature surface coil tunable to both the 1 H and 19 F frequencies (400.2 and 376.6 MHz, respectively). To acquire coil-localized spectra of 19 F (128 scans) the coil was positioned at 4 different places, the chest, abdomen, left flank, and the right thigh to cover primarily the liver, the lungs, the spleen, and the tumor, respectively. In 3 mice, the 19 F spectroscopic signal was deemed sufficient for 19 F-MRI (signal-to-noise ratio (SNR) >200). In these mice a stack of 6 axial 1 H images of the liver was acquired with a gradient echo sequence (repetition time (TR) 29.7 ms, echo time (TE) 1.9 ms, signal averages 4, matrix 128×128, field of view 30×30 mm 2 , slice thickness 2 mm, total acquisition time 15.2 s).
Next, a stack of axial 19 F images was acquired at the identical position as the 1 H images using a fast spin echo sequence (TR = 500 ms, TE = 3.7 ms; echo-train length 4, signal averages 960, matrix 16x16, field of view 30×30mm 2 , slice thickness 2 mm, total acquisition time 32 minutes).
Organ collection
Immediately after the MRI session the mice were euthanized by cervical dislocation to harvest the liver, lungs, spleen and tumor. A single-cell suspension was then prepared from the different organs using a cell strainer (70 μm) and RPMI medium. The different cell suspensions were washed once with RPMI and then split into two groups with 5% of the cell suspension used for flow cytometry analyses and 95% for high resolution ex-vivo spectroscopy 19 F-NMR analyses.
High resolution ex-vivo 19 F-NMR spectroscopy of excised organs 
Statistical analyses
Values are given as means ± standard deviation. Analyses of differences between groups were performed using unpaired Student's t-test and one-way analysis of variance (ANOVA) where appropriate (GraphPad Prism software).
Results
In vitro labeling and function of immune cells
The 3 cell groups were in-vitro labeled or not with FITC conjugated or unconjugated 19 F -PFC in order to assess cell labeling efficiency, and to compare cell viability, phenotype and T cell function. After 18 hours of incubation with PFC the cells were stained by Trypan blue exclusion assay to evaluate the potential cytotoxicity due to labeling. For the 3 cell groups (SP, T act and T OVA-act ), the amount of dead cells after PFC incubation was comparable to the untreated control condition (difference when compared to untreated cells of the same type: 0.5%, 7% and 3% for SP, T act , and T OVA-act , respectively). This result shows that the PFC-based protocol safely labels these cells invitro. Moreover, PFC labeling does not affect the proportion of cell populations, no difference was observed after FITC-conjugated PFC staining (Fig 2) . SP are composed of~25% of CD3 + T cells (Fig 2A) ,~55% of CD19 + non-T cells (Fig 2B) ,~5% of CD11b + non-T cells (Fig 2C) , whereas T act and T OVA-act are composed of only CD3 + T lymphocytes (Fig 2A) . In CD3 + T cells, almost all cells are CD8 + T cells (Fig 2A) because they are derived from transgenic OT-1 mice. Fig 4A) . In the T act and in T OVA-act groups the percentage of PFC + cells are 13.70% ± 0.61% and 28.67% ± 7.30%, respectively, n = 3 ( Fig 4A) . Non-T cells were preferentially labeled by PFC and T OVA-act presented a 2-fold higher labeling than T act . In the SP group, the majority of lymphocytes are naïve T cells (54,96% ± 5.91% of CD62L (Fig 4B) . The proportion of these 2 populations is different in T act and T OVA-act . OVA-peptide stimulation preferentially induces an effector memory (62.80% ± 6.25%, n = 3) rather than a central memory phenotype (34.13% ± 5.85%, n = 3). Conversely, antibody stimulation leads to a higher central memory (50.73% ± 5.29, n = 3) than effector memory phenotype (43.33% ± 4.72, n = 3). Moreover OVA-peptide stimulation is stronger than antibody stimulation in our experimental conditions as it induces an overexpression of PD-1 (88.83% ± 0.82%, n = 3) compared to T act cells (46.63% ± 3.62%, n = 3). All of these phenotypic differences may impact PFC uptake.
Finally to determine the impact of PFC on T cell function, we performed a series of experiments before and after PFC-labeling. As expected, SP showed a weak response due to the small proportion of CD3 + T lymphocytes (Fig 5) . PFC-labeling induced a decrease of response in CD107a upregulation ( Fig 5A) and IFNγ (Fig 5B) secretion assays, but did not impact the cytotoxic capacity of T cells (Fig 5C) . Hence, PFC-labeled T cells are able to recognize and kill their target.
Limit of detection of 19
F-PFC-labeled immune cells by 19 
F-MRI
In order to determine the limit of detection of the method, a phantom experiment was performed using different TFA dilutions (Fig 6A and 6B F images were acquired for each dilution (Fig 6C) . Under these conditions the limit of detection for F atoms/cell (Fig 6E) corresponding to 238'000 cells per μl.
In-vivo detection of 19 
F-MRI signal
In order to follow the migration of the injected immune cells in-vivo, 19 F-MRS was performed in different anatomic areas (chest, abdomen, left flank and right thigh) of the mice injected 
Flow cytometry
In order to confirm the label tracking results from in-vivo 19 F-MRS, in-vivo 19 F-MRI, and exvivo 19 F-NMR, the distribution of the donor T cells in the different organs was determined by flow cytometry according to their expression of CD3, CD8 and CD45.2. There was massive infiltration and proliferation of donor cells in a variety of peripheral tissues, including liver, spleen, and lungs (Fig 10) . A small population of these donor cells (CD3 + CD8 + CD45.2 + ) was also found in the tumors, with no significant difference between the 3 cell types. However, contrary to what was observed with in-vivo and ex-vivo 19 F-analyses, the amount of adoptively transferred SP was very low in all the organs analyzed and the amount of adoptively transferred T OVA-act more abundant in the different organs compared to either SP or T act , although not to a significant degree (liver: p = 0.1313; lungs: p = 0.1073; spleen: p = 0.109).
Discussion
In this study 19 F-PFC was used to in-vitro label SP and activated T cells and to follow their migration in-vivo in B16-OVA-melanoma bearing mice using 19 F-MRS and 19 F-MRI.
In-vitro labeling of immune cells and the detection threshold by [4] . In the present study there are, however, some differences compared to the study of Srinivas. We used a commercially available PFC, while Srinivas et al. used a perfluorinated polyether emulsion prepared in their own lab, which required 3 days of incubation to label cells, in contrast to the 18h-incubation in the present protocol. Importantly, the labeling procedure used in the current work did not affect cell viability.
With an in-vitro phantom experiment we determined the detection threshold for 19 F-MRI for in-vitro 
F-MRI
Initially, 19 F-PFC labeled SP were tested in non-tumor bearing mice as a proof of concept.
Using in-vivo 19 F-MRS we detected the donor cells in the area of the abdomen, the chest, and the left flank corresponding mainly to the liver, the lungs, and the spleen, respectively (Fig 8A) . These in-vivo data were confirmed post-mortem by in-vitro quantitative 19 Our data show that following IV injection of in-vitro 19 F-labeled cells, the majority of injected cells are trapped in the liver and the lungs (Fig 8B) . It has previously been shown that a large fraction of IV-injected CD8 + T cells preferentially migrate into the interstitium of normal lungs [24] . In fact, that study suggested that peripheral homing and retention of CD8 + T cells in the respiratory tract is a mechanism to ensure an adequate number of memory T cells being available at the site of potential future respiratory tract infections. Using in-vivo 19 F-MRS we detected the donor cells in the area of the abdomen (corresponding mainly to the liver), the chest (corresponding mainly to the lungs and a portion of the liver) and the left flank (corresponding to the spleen and a portion of the liver) (Fig 8B) 
SP and T cell behavior after IV injection
While ex-vivo high-resolution flow cytometry were detected in the liver by 19 F-MRI, one would expect to also image T act and T OVA-act as they were observed in the organs at a considerably higher percentage than SP (i.e. 0.07% to 0.71%, for T act 0.35% to 2.94% for T OVA-act in the various organs; Fig 10A) . However, 19 F was detected by 19 F-MRI in only one T act treated mouse. This low rate of detection could be explained by the fact that following both antibody (against CD3 and CD28) and peptide stimulation, both T act and T OVA-act have the capacity to divide rapidly in-vivo. This proliferation of T cells in-vivo would then induce a subsequent dilution of the PFC content in the daughter cells. This dilution of 19 F signal in the daughter cells can be verified in the present study by comparing the ex-vivo high resolution spectroscopy data to flow cytometry data. The flow cytometry data also demonstrate that T OVA-act have a better capacity than T act and SP to infiltrate the different organs and the tumor. Both, T act and T OVA-act were produced from OT-1 mice and therefore, both T cells are expected to present predominantly the TCR that recognizes the OVA antigen. Nevertheless, flow cytometry in Fig 10A and 10B demonstrates a trend towards higher infiltration of tumors by T OVA-act . In line with the high presence of T OVA-act in the liver, lungs, spleen, and tumor, they were detected by 19 F-MRS but not at a 19 F signal level that allowed for imaging. This is in contrast to SP, which are detectable by imaging even with their low presence in these organs. The SP represent a heterogeneous population. Besides T and B cells they contain dendritic cells and macrophages, both of which are phagocytic and can accumulate 10 to 1000 times more 19 F compared to T cell populations [25] . Also, as these phagocyte populations are terminally differentiated cells, they do not divide, unlike activated T cells. 
